In Alzheimer’s disease and mild cognitive impairment, elevated cerebrospinal fluid neurogranin levels correlate strongly with cognitive decline and progression, while blood-derived exosomal neurogranin has shown promise as a minimally invasive biomarker of early synaptic degeneration. Here, NRGN is linked to Alzheimer disease.